RVL Pharmaceuticals plc
RVLPDelisted Nov 20, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001739426
RVL Pharmaceuticals plc was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Oct 23, 2023; 32 institutions reported holding it in 13F filings for Q3 2023, worth $1.57M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding RVL Pharmaceuticals plc changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 46 | 35 | −11 |
| Shares | 4.83M | 4.03M | −795.3K (−16.5%) |
| Value | $14.5M | $11.9M | −$2.67M (−18.4%) |
New holders (1)
Institutions that held RVL Pharmaceuticals plc at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nations Financial Group Inc, | 12,500 | $37.0K | 0.01% |
Sold out (12)
Institutions that held RVL Pharmaceuticals plc at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Jacobs Levy Equity Management, Inc | 339,129 | $1.02M |
| Squarepoint Ops LLC | 80,827 | $243.0K |
| Charles Schwab Investment Management Inc | 61,991 | $187.0K |
| Marshall Wace, LLP | 57,958 | $174.0K |
| Hancock Whitney Corp | 53,724 | $162.0K |
| Jane Street Group, LLC | 35,028 | $105.0K |
| Credit Suisse AG | 27,966 | $84.0K |
| ExodusPoint Capital Management, LP | 12,077 | $36.0K |
| Raymond James & Associates | 10,600 | $32.0K |
| Mirae Asset Global Investments Co., Ltd. | 1,020 | $3.00K |
| Captrust Financial Advisors | 730 | $2.00K |
| New York State Common Retirement Fund | 111 | $0 |